Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Biogen vs. Gilead Sciences

TheMotleyFool

0 0

Better Buy: Biogen vs. Gilead SciencesPhoto, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Despite a strong year for biotechnology stocks, Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD) both underwhelmed investors in 2019. Biogen's shares ended the year down 1.4%, whereas Gilead's stock eked out a modest gain of 3.88%. By contrast, the biotech funds iShares Nasdaq Biotechnology ETF and SPDR S&P Biotech ETF rose a healthy 25% and 32.5%, respectively, last year.

Which of these biotech giants has the better chance of breaking out of this funk in 2020? Let's take a look at how Biogen and Gilead compare on several key areas to find out.

Image source: Getty Images.

Source Fool.com

Like: 0

GILD

Share